Biomarker Expression in Samples From Young Patients With Anaplastic Large Cell Lymphoma

Lymphoma Clinical Trial

Official title:

Expression of T Immunoregulatory Proteins in ALK+ Anaplastic Large Cell Lymphoma (ALCL)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01366170
• Other study ID #: ANHL11B1
• Secondary ID: COG-ANHL11B1NCI-
• Status: Completed
• Phase: N/A
• First received: June 2, 2011
• Last updated: May 17, 2016
• Start date: May 2011

Study information

• Verified date: May 2016
• Source: Children's Oncology Group
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Observational

Clinical Trial Summary

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. it may also help doctors predict how patients will respond to treatment.

PURPOSE: This research trial studies biomarker expression in tissue samples from young patients with anaplastic large cell lymphoma.

Description:

OBJECTIVES:

• To determine the expression of immunoregulatory proteins including CD4, FOXP3 and CD276 in anaplastic large cell lymphoma (ALCL).

• To correlate the expression of these proteins with the levels of anaplastic lymphoma kinase (ALK) autoantibodies in patient of ANHL0131.

OUTLINE: Archived tissue microarray samples are analyzed by mass spectrometry and validated by Western blotting, flow cytometry, and IHC.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 7
• Est. primary completion date: May 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A to 20 Years

Eligibility

DISEASE CHARACTERISTICS:

• Diagnosis of anaplastic large cell lymphoma

• Tissue microarray samples available from the Cooperative Human Tissue Network (CHTN)

PATIENT CHARACTERISTICS:

• Not specified

PRIOR CONCURRENT THERAPY:

• Not specified

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, Large-Cell, Anaplastic
• Lymphoma, Non-Hodgkin

Intervention

Genetic:
• microarray analysis

• protein expression analysis

• western blotting

Other:
• flow cytometry

• immunohistochemistry staining method

• laboratory biomarker analysis

• mass spectrometry

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Children's Oncology Group	National Cancer Institute (NCI)

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Expression of immunoregulatory proteins including CD4, FOXP3 and CD276 in ALCL			No
Primary	Correlation of CD4, FOXP3, and CD276 with ALK autoantibody response in patients enrolled in ANHL0131			No